BioCryst Pharmaceuticals Inc (BCRX) - Net Assets
Based on the latest financial reports, BioCryst Pharmaceuticals Inc (BCRX) has net assets worth $-119.15 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($514.16 Million) and total liabilities ($633.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BCRX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-119.15 Million |
| % of Total Assets | -23.17% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -7650.89% |
| Growth Volatility | 1044.38 |
BioCryst Pharmaceuticals Inc - Net Assets Trend (1994–2025)
This chart illustrates how BioCryst Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore BioCryst Pharmaceuticals Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for BioCryst Pharmaceuticals Inc (1994–2025)
The table below shows the annual net assets of BioCryst Pharmaceuticals Inc from 1994 to 2025. For live valuation and market cap data, see BioCryst Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-119.15 Million | +74.96% |
| 2024-12-31 | $-475.93 Million | -4.48% |
| 2023-12-31 | $-455.53 Million | -54.63% |
| 2022-12-31 | $-294.60 Million | -175.36% |
| 2021-12-31 | $-106.99 Million | -455.43% |
| 2020-12-31 | $-19.26 Million | -150.36% |
| 2019-12-31 | $38.25 Million | -22.31% |
| 2018-12-31 | $49.23 Million | -41.22% |
| 2017-12-31 | $83.77 Million | +5208.43% |
| 2016-12-31 | $1.58 Million | -96.69% |
| 2015-12-31 | $47.72 Million | -36.90% |
| 2014-12-31 | $75.64 Million | +6817.14% |
| 2013-12-31 | $-1.13 Million | -148.02% |
| 2012-12-31 | $-454.00K | -103.07% |
| 2011-12-31 | $14.81 Million | -77.78% |
| 2010-12-31 | $66.62 Million | -22.77% |
| 2009-12-31 | $86.27 Million | +85.81% |
| 2008-12-31 | $46.43 Million | -28.47% |
| 2007-12-31 | $64.91 Million | +206.81% |
| 2006-12-31 | $21.16 Million | -63.80% |
| 2005-12-31 | $58.44 Million | +99.22% |
| 2004-12-31 | $29.33 Million | +3.12% |
| 2003-12-31 | $28.45 Million | -29.11% |
| 2002-12-31 | $40.13 Million | -29.37% |
| 2001-12-31 | $56.81 Million | -7.59% |
| 2000-12-31 | $61.48 Million | -13.89% |
| 1999-12-31 | $71.40 Million | +157.76% |
| 1998-12-31 | $27.70 Million | +9.49% |
| 1997-12-31 | $25.30 Million | -28.53% |
| 1996-12-31 | $35.40 Million | +213.27% |
| 1995-12-31 | $11.30 Million | +0.89% |
| 1994-12-31 | $11.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioCryst Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 148467900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.13 Million | % |
| Other Comprehensive Income | $38.00K | % |
| Other Components | $1.38 Billion | % |
| Total Equity | $-119.15 Million | 100.00% |
BioCryst Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of BioCryst Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gelsenwasser AG
F:WWG
|
$1.87 Billion |
|
AT & S Austria Technologie & Systemtechnik Aktiengesellschaft
VI:ATS
|
$1.87 Billion |
|
AUTOHOME INC. A DL -01
F:8AHA
|
$1.88 Billion |
|
Omnicell Inc
NASDAQ:OMCL
|
$1.88 Billion |
|
Tianrun Crankshaft Co Ltd
SHE:002283
|
$1.87 Billion |
|
Shanghai DaZhong Public Utilities Group Co Ltd
SHG:600635
|
$1.87 Billion |
|
Nanhua Futures Co Ltd
SHG:603093
|
$1.87 Billion |
|
Jihua Group Corp Ltd
SHG:601718
|
$1.87 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioCryst Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -475,934,000 to -119,153,000, a change of 356,781,000.
- Net income of 263,861,000 contributed positively to equity growth.
- New share issuances of 59,000 increased equity.
- Other comprehensive income decreased equity by 883,000.
- Other factors increased equity by 93,744,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $263.86 Million | +221.45% |
| Share Issuances | $59.00K | +0.05% |
| Other Comprehensive Income | $-883.00K | -0.74% |
| Other Changes | $93.74 Million | +78.68% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares BioCryst Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-12-31 | $1.66 | $9.19 | x |
| 1995-12-31 | $1.26 | $9.19 | x |
| 1996-12-31 | $3.17 | $9.19 | x |
| 1997-12-31 | $1.84 | $9.19 | x |
| 1998-12-31 | $1.96 | $9.19 | x |
| 1999-12-31 | $4.64 | $9.19 | x |
| 2000-12-31 | $3.24 | $9.19 | x |
| 2001-12-31 | $3.24 | $9.19 | x |
| 2002-12-31 | $2.27 | $9.19 | x |
| 2003-12-31 | $1.61 | $9.19 | x |
| 2004-12-31 | $1.39 | $9.19 | x |
| 2005-12-31 | $2.27 | $9.19 | x |
| 2006-12-31 | $0.73 | $9.19 | x |
| 2007-12-31 | $1.98 | $9.19 | x |
| 2008-12-31 | $1.22 | $9.19 | x |
| 2009-12-31 | $2.22 | $9.19 | x |
| 2010-12-31 | $1.49 | $9.19 | x |
| 2011-12-31 | $0.33 | $9.19 | x |
| 2012-12-31 | $-7.94 | $9.19 | x |
| 2013-12-31 | $-7.66 | $9.19 | x |
| 2014-12-31 | $-7.01 | $9.19 | x |
| 2015-12-31 | $-7.01 | $9.19 | x |
| 2016-12-31 | $-7.68 | $9.19 | x |
| 2017-12-31 | $-7.48 | $9.19 | x |
| 2018-12-31 | $-7.09 | $9.19 | x |
| 2019-12-31 | $0.33 | $9.19 | x |
| 2020-12-31 | $-6.12 | $9.19 | x |
| 2021-12-31 | $-0.60 | $9.19 | x |
| 2022-12-31 | $-1.58 | $9.19 | x |
| 2023-12-31 | $-2.37 | $9.19 | x |
| 2024-12-31 | $-2.30 | $9.19 | x |
| 2025-12-31 | $-0.55 | $9.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioCryst Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 30.16%
- • Asset Turnover: 1.70x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-46.73%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | -61.61% | -985.71% | 0.05x | 1.14x | $-8.02 Million |
| 1995 | -76.11% | -4300.00% | 0.02x | 1.16x | $-9.73 Million |
| 1996 | -21.75% | -285.19% | 0.07x | 1.05x | $-11.24 Million |
| 1997 | -41.90% | -1060.00% | 0.04x | 1.05x | $-13.13 Million |
| 1998 | -17.33% | -75.00% | 0.22x | 1.05x | $-7.57 Million |
| 1999 | -7.42% | -212.00% | 0.03x | 1.03x | $-12.44 Million |
| 2000 | -18.83% | -349.19% | 0.05x | 1.15x | $-17.73 Million |
| 2001 | -8.78% | -44.69% | 0.19x | 1.04x | $-10.67 Million |
| 2002 | -42.19% | -953.98% | 0.04x | 1.03x | $-20.94 Million |
| 2003 | -44.64% | -777.23% | 0.05x | 1.06x | $-15.54 Million |
| 2004 | -71.94% | -6264.19% | 0.01x | 1.11x | $-24.04 Million |
| 2005 | -44.66% | -17185.28% | 0.00x | 1.70x | $-31.94 Million |
| 2006 | -206.18% | -702.16% | 0.09x | 3.24x | $-45.73 Million |
| 2007 | -44.77% | -40.79% | 0.50x | 2.20x | $-35.55 Million |
| 2008 | -53.27% | -43.73% | 0.67x | 1.82x | $-29.37 Million |
| 2009 | -15.59% | -18.03% | 0.52x | 1.65x | $-22.08 Million |
| 2010 | -49.13% | -51.55% | 0.57x | 1.66x | $-39.40 Million |
| 2011 | -384.63% | -289.91% | 0.24x | 5.55x | $-58.43 Million |
| 2012 | 0.00% | -148.64% | 0.46x | 0.00x | $179.10K |
| 2013 | 0.00% | -173.72% | 0.35x | 0.00x | $12.16 Million |
| 2014 | 0.00% | -332.08% | 0.10x | 0.00x | $1.60 Million |
| 2015 | 0.00% | -89.15% | 0.39x | 0.00x | $8.07 Million |
| 2016 | 0.00% | -209.25% | 0.29x | 0.00x | $1.46 Million |
| 2017 | 0.00% | -261.18% | 0.14x | 0.00x | $-2.60 Million |
| 2018 | 0.00% | -490.25% | 0.14x | 0.00x | $-28.06 Million |
| 2019 | -284.68% | -222.99% | 0.28x | 4.58x | $-112.72 Million |
| 2020 | 0.00% | -1026.35% | 0.05x | 0.00x | $-80.47 Million |
| 2021 | 0.00% | -117.11% | 0.27x | 0.00x | $-173.36 Million |
| 2022 | 0.00% | -91.24% | 0.49x | 0.00x | $-217.66 Million |
| 2023 | 0.00% | -68.36% | 0.64x | 0.00x | $-180.99 Million |
| 2024 | 0.00% | -19.72% | 0.92x | 0.00x | $-41.29 Million |
| 2025 | 0.00% | 30.16% | 1.70x | 0.00x | $275.78 Million |
Industry Comparison
This section compares BioCryst Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $459,373,250
- Average return on equity (ROE) among peers: -63.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioCryst Pharmaceuticals Inc (BCRX) | $-119.15 Million | -61.61% | N/A | $1.87 Billion |
| Aurora Cannabis Inc (ACB) | $605.09 Million | 0.26% | 0.40x | $197.35 Million |
| Akanda Corp (AKAN) | $26.90 Million | -43.34% | 0.45x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $1.82 Billion | 13.28% | 0.39x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $164.76 Million | -183.14% | 0.18x | $1.77 Billion |
| Amphastar P (AMPH) | $337.33 Million | 1.34% | 0.35x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $366.97 Million | 2.90% | 9.74x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $15.92 Million | -75.48% | 0.12x | $1.80 Billion |
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to… Read more